PBAC's latest decision on Momelotinib: Recommended with restriction (2024). Considered for Treatment of intermediate or high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in patients with moderate to severe anaemia who are JAK inhibitor naïve or have been treated with ruxolitinib.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adult patients with intermediate or high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis with moderate to severe anaemia (haemoglobin < 100 g/L) who are JAK inhibitor naïve or previously treated with ruxolitinib.
Therapy area
Haematology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Spleen volume reduction and total symptom score
Key trials
SIMPLIFY-1, SIMPLIFY-2, MOMENTUM
Comparator
ruxolitinib
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.